Sycrest News and Research

RSS
Merck reports $342 million net income for 2010 third quarter

Merck reports $342 million net income for 2010 third quarter

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

Lundbeck, Merck announce commercialization agreement for SYCREST sublingual tablets

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

European Commission approves MSD's MAA for SYCREST in manic episodes associated with bipolar I disorder

Merck reports strong bottom-line performance in second quarter

Merck reports strong bottom-line performance in second quarter

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

CHMP adopts positive opinion on pending MAA for SYCREST sublingual tablets

Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market

Emerging oral atypical antipsychotics to compete in increasingly crowded schizophrenia drug market

Final results of SAPHRIS clinical study released

Final results of SAPHRIS clinical study released

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder

Schering-Plough announces European filing of Sycrest (asenapine) for schizophrenia and bipolar I disorder